Medullary Thyroid Cancer-Current Treatment Strategy, Novel Therapies and Perspectives for the Future

Hormones and Cancer

Volumn 3, Issue 5-6, 2012, Pages 218-226

  Sugawara, Masahiro ^a   Ly, Tran ^a   Hershman, Jerome M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CABOZANTINIB; CAPECITABINE; DOXORUBICIN; INDOMETACIN; IODINE 131; MOTESANIB; PLACEBO; PROTEIN RET; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CEREBROVASCULAR ACCIDENT; CONSTIPATION; DEHYDRATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM PERFORATION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; GALLBLADDER DISEASE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFECTION; LARYNX EDEMA; LEUKOPENIA; LUNG EMBOLISM; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; RASH; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

EID: 84869084378     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-012-0119-5     Document Type: Review

References (56)

1. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Fharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19: 565-612.
2. Pelizzo MR, Boschin IM, Bernaante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC, Rubello D (2007) Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 33: 493-497.
3. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, Schlumberger M (2003) Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88: 2070-2075.
4. Machens A, Hauptmann S, Dralle H (2008) Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 95: 586-591.
5. Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, Klar E (2001) Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130: 1044-1049.
6. Ito Y, Miyauchi A, Yabuta T, Fukushima M, Inoue H, Tomoda C, Uruno T, Kihara M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F (2009) Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: experience of a single institution. World J Surg 33: 58-66.
7. Westerlund J, Andersson L, Carlsson T, Zoppoli P, Fagman H, Nilsson M (2008) Expression of Islet1 in thyroid development related to budding, migration, and fusion of primordia. Dev Dyn 237: 3820-3829.
8. Zhang P, Zuo H, Ozaki T, Nakagomi N, Kakudo K (2006) Cancer stem cell hypothesis in thyroid cancer. Pathol Int 56: 485-489.
9. Lanzi C, Cassinelli G, Nicolini V, Zunino F (2009) Targeting RET for thyroid cancer therapy. Biochem Pharmacol 77: 297-309.
10. Panigrahi B, Roman SA, Sosa JA (2010) Medullary thyroid cancer: are practice patterns in the United States discordant from American Thyroid Association Guidelines? Ann Surg Oncol 17: 1490-1498.
11. Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107: 2134-2142.
12. Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF, GTE Study Group (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90: 6077-6084.
13. Sugawara M, Geffner DL, Martinez D, Hershman JM (2009) Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes 16: 367-372.
14. Elisei R, Cosci B, Romei C, Bottici V, Renzini F, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A (2008) Prognostic significance of somatic ret oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93: 682-687.
15. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL (2010) Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20: 863-871.
16. Verbeek HH, Alves MM, de Groot JW, Osinga J, Plukker JT, Links TP, Hofstra RM (2011) The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 96: E991-E995.
17. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28: 767-772.
18. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R (2010) Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95: 2664-2671.
19. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial. J Clin Oncol 30: 134-141.
20. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinksy DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26: 4708-4713.
21. Rosen LS, Kurzrock R, van Mulay M, Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun Y, Bass MB, Xu Y, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS (2007) Safety, pharmokinetics and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 2369-2376.
22. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27: 3794-3801.
23. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MN, Salgia R (2011) Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29: 2660-2666.
24. Lam ET, Ringel MD, Kloos RT et al (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28: 2323-2330.
25. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in the UK based population. Eur J Endocrinol 165: 315-322.
26. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman AI, Kurzrock R (2011) Inhibition of the Ras/Raf/MEK/ERk and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96: 997-2005.
27. De Souza JA, Busaidy N, Zimrin A, Seiwert TY, Villaflor VM, Poluru KB, Reddy PL, Nam J, Vokes E, Cohen EE (2010) Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol 28: 15s (suppl; abstr 5504).
28. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG (2010) Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16: 5260-5268.
29. Pacini F, Castagna MG, Cipri C, Schlumberger M (2010) Medullary thyroid carcinoma. Clin Oncol 22: 475-485.
30. Labidi SI, Gravis G, Tarpin C, Brun V, Viens P (2007) Medullary thyroid cancer treated by capecitabine. Anticancer Drugs 18: 831-834.
31. Paiva CE, Michelin OC (2008) Use of capecitabine in refractory metastatic medullary thyroid carcinoma. Thyroid 18: 587.
32. Gilliam LK, Kohn AD, Lalani T, Swanson PE, Vasko V, Patel A, Livingston RB, Pickett CA (2006) Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid 16: 801-810.
33. Wang HM, Zhang GY (2005) Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo. World J Gastroenterol 11: 340-343.
34. Huang RH, Chai J, Tarnawski AS (2006) Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells. World J Gastroenterol 12: 6446-6452.
35. Kundu N, Walser TC, Ma X, Fulton AM (2005) Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 54: 981-987.
36. He H, Xia HH, Wang JD, Gu Q, Lin MC, Zou B, Lam SK, Chan AO, Yuen MF, Kung HF, Wong BC (2006) Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma. Cancer 106: 1243-1249.
37. de Groot DJ, van der Deen M, Le TK, Regeling A, de Jong S, de Vries EG (2007) Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer 97: 1077-1083.
38. Quidville V, Segond N, Pidoux E, Cohen R, Jullienne A, Lausson S (2004) Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase. Endocrinology 145: 2561-2571.
39. Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A (2006) 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat 81: 14-30.
40. Tomoda C, Moatamed F, Naeim F, Hershman JM, Sugawara M (2008) Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood) 233: 1433-1440.
41. Samaan NA, Schultz PN, Hickey RC (1988) Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67: 801-805.
42. Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD (2010) Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 102: 175-178.
43. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, Rosenthal DI, Hoff A, Evans DB, Clayman GL, Garden AS, Sherman SI (2008) Postoperative radiotherapy for advanced medullay thyroid cancer-local disease control in the modern era. Head Neck 30: 883-888.
44. Rosenbluth BD, Serrano V, Happersett L, Shaha AR, Tuttle RM, Narayana A, Wolden SL, Rosenzweig KE, Chong LM, Lee NY (2005) Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. Int J Radiat Oncol Biol Phys 63: 1419-1426.
45. Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J (2006) French Endocrine Tumor Group. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24: 1705-1711.
46. Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, Krenning EP (1993) In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76: 1413-1417.
47. Mato E, Matías-Guiu X, Chico A, Webb SM, Cabezas R, Berna L, De Leiva A (1998) Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab 83: 2417-2420.
48. Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M, Lopera Sierra M, Cremonesi M, Chinol M, Macke HR, Paganelli G (2004) Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopham 19: 65-71.
49. Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJ, Ziekman PG, Koten JW (2008) Local therapy of cancer with free IL-2. Cancer Immunol Immunother 57: 931-950.
50. Auernhammer CJ, Melmed S (2000) Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev 21: 313-345.
51. Arthan D, Hong SK, Park JI (2010) Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Lett 297: 31-41.
52. Davis ID, Kiers L, MacGregor L, Quinn M, Arezzo J, Green M, Rosenthal M, Chia M, Michael M, Bartley P, Harrison L, Daly M (2005) A randomized, double-blinded, placebo-controlled phase ii trial of recombinant human leukemia inhibitory factor (rhuLIF, Emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 11: 1890-1898.
53. Eichelbaum EJ, Vesely BA, Alli AA, Sun Y, Gower WR Jr, Vesely DL (2006) Four cardiac hormones eliminate up to 82% of human medullary thyroid carcinoma cells within 24 hours. Endocrine 30: 325-332.
54. Kong X, Wang X, Xu W, Behera S, Hellermann G, Kumar A, Lockey RF, Mohapatra S, Mohapatra SS (2008) Natriuretic peptide receptor A as a novel anticancer target. Cancer Res 68: 249-256.
55. Bierwolf C, Burgemeister A, Lüthke K, Born J, Fehm HL (1998) Influence of exogenous atrial natriuretic peptide on the pituitary-adrenal response to corticotropin-releasing hormone and vasopressin in healthy men. J Clin Endocrinol Metab 83: 1151-1157.
56. Yalcin M, Dyskin E, Lansing L, Bharali DJ, Mousa SS, Bridoux A, Hercbergs AH, Lin HY, Davis FB, Glinsky GV, Glinskii A, Ma J, Davis PJ, Mousa SA (2010) Tetraiodothyroacetic acid (Tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 95: 1972-1980.